Abstract 1984P
Background
In the era of precision medicine, despite mounting evidence that women might be more susceptible to toxicity from chemotherapy (CT), sex influence on treatment effects and the biology of non-sex-related cancers have largely been ignored. Due to their rarity, data on patients (pts) with sarcoma are scarce.
Methods
We reviewed data of pts with sarcoma treated between 2015 and 2022 at Veneto Institute of Oncology. Delays/reductions were evaluated in the first 9 weeks of CT and expressed as relative dose intensity (RDI): ratio of delivered dose intensity (mg/m2 per week) to theorical dose intensity. Kaplan-Meier, log-rank and Cox regressions were used. Sex differences in RDI, adverse events (AEs) and impact of RDI on disease-free survival (DFS), progression-free survival (PFS) and overall survival (OS) were analyzed.
Results
Overall, data for 197 pts were available (109 treatments for localized disease: 69 neoadjuvant/40 adjuvant setting; 127 first -line treatments for advanced disease). Median age was 57 years, males were 112 (57%). Soft tissue sarcomas were 167 (85%), bone sarcomas were 30 (15%). Grade ≥ 3 AEs were observed in 60% of pts. Male had a lower risk of severe non-hematologic AEs (OR 0.5; p=0.04), while no significant sex differences were observed for all severe AEs. Dose was reduced upfront in 46% of female Vs 28% of males (p=0.007). Also, males less often had RDI <85% (OR 2.4; p=0.002). Survival outcomes were similar in both sexes, though comparisons might suffer from biases due to different distribution of histotypes within sexes. In the localized disease setting, worse survival was observed for males receiving RDI <85% compared to ≥85% (median OS 36.6 m Vs 63.7 m, p=0.004; median DFS 11.1 m Vs 26.3 m, p=0.03) whereas no significant differences at the 85% threshold of RDI were found for females.
Conclusions
Greater risk of AEs and lower RDI in women treated for sarcoma add to the evidence that a sex-difference in treatment delivery and outcomes exists. Despite a global lower RDI, survival outcomes for female were not worse compared to male. Interestingly, RDI <85% did not negatively affect survival outcomes in women (standard dosing based on "male" standards?). Such data call for optimization of drug dosing by sex to be considered in trial design.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
U. Basso: Financial Interests, Personal, Advisory Board: BMS; Financial Interests, Personal, Invited Speaker: Ipsen, Janssen, Astellas, AstraZeneca, MSD, Merck; Financial Interests, Institutional, Funding, Research Grants: Ipsen. A. Brunello: Financial Interests, Personal, Advisory Board: PharmaMar, Boehringer Ingelheim, Deciphera; Financial Interests, Personal, Invited Speaker: GSK; Financial Interests, Institutional, Local PI: Roche, Deciphera, Boehringer Ingelheim, Rain Therapeutics. All other authors have declared no conflicts of interest.
Resources from the same session
1830P - CBP-1018, a bi-ligand-drug conjugate treated in patients with advanced solid tumors: A phase I, multi-center, open-label, dose-escalation and dose expansion study
Presenter: Kaiwen Li
Session: Poster session 15
1831P - Dissecting the meaning of obesity in metastatic castration resistant prostate cancer: Size or metabolism?
Presenter: Lisa Horvath
Session: Poster session 15
1832P - Centralized screening for homologous recombination repair (HRR) genes in metastatic castration-resistant prostate cancer (mCRPC): A feasibility study from a multicenter Spanish cohort
Presenter: Javier Freire
Session: Poster session 15
1833P - Concurrent high-dose IV Vitamin C (IVC) and docetaxel for metastatic castrate-resistant prostate cancer (mCRPC): A randomized, placebo-controlled, double-blind phase II trial
Presenter: Channing Paller
Session: Poster session 15
1834P - Exposure-efficacy analyses of talazoparib in combination with enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC) in the TALAPRO-2 trial
Presenter: Arun Azad
Session: Poster session 15
1835P - A prospective study to determine the prevalence of DNA repair defects in patients (pts) with advanced prostate cancer (PC)
Presenter: Shahneen Sandhu
Session: Poster session 15
1836P - Blood based biomarkers identify metastatic castration-resistant prostate cancer (mCRPC) with the greatest benefit from continuing enzalutamide (ENZ) beyond progression in combination with docetaxel (Doc): A pre-specified biomarker study of the phase IIIb PRESIDE trial
Presenter: Maria Ruiz Vico
Session: Poster session 15
1837P - Assessing PSA
Presenter: Susan Halabi
Session: Poster session 15
1839P - Circulating tumor DNA (ctDNA) low pass whole genome sequencing (lpWGS) studies identify genomic alterations associating with taxane outcomes in prospective phase III taxane trials for metastatic castration resistant prostate cancer (mCRPC) sufferers
Presenter: George Seed
Session: Poster session 15